Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

alogliptin-metFORMIN

alogliptin-metFORMIN
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Kazano TABLET, ORAL 12.5 mg-500 mg, 12.5 mg-1,000 mg    
Comments:

ORDERED FORMULATION

THERAPEUTIC INTERCHANGE

alogliptin-metFORMIN (Kazano)                                                

  • 12.5 mg-500 mg tablet BID                                                                                                
  • 12.5 mg-1,000 mg tablet BID

alogliptin (Nesina) AND metFORMIN (Glucophage)

  • ONE 12.5 mg alogliptin tablet PLUS ONE 500 mg metFORMIN BID
  • ONE 12.5 mg alogliptin tablet PLUS ONE 1,000 mg metFORMIN BID

Kazano medication guide

metFORMIN -- hold for 48 hours post IV contrast media per radiologist, contraindications with CHF, renal disease, hepatic disease, and age. Pharmacist may order SCr.

Reviewed: July 23, 2013 (Kazano)

Last updated: Dec. 19, 2017






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved